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The potential of proteasome inhibition in tumor therapy 
was  first  suggested  by  the  success  of  the  proteasome 
inhibitor  bortezomib  in  the  treatment  of  multiple 
myeloma, for which at the time of its approval in 2003 
there was no effective therapy. Since then, the emergence 
of side effects and resistance [1] on the one hand, and the 
hope of developing the approach for other tumors on the 
other hand have led to extensive efforts to delineate the 
molecular mechanisms underlying the clinical effective­
ness of proteasome inhibition with the aim of identifying 
new drugs acting on the same pathway. The discovery, 
now reported in BMC Biology by Zhao and Vuori, of an 
obligatory  role  for  the  focal  adhesion  protein  p130Cas 
(Cas)  in  the  cytotoxicity  of  bortezomib  and  a  second 
proteasome  inhibitor,  MG132,  illustrates  some  of  the 
issues arising in connection with this quest.
Pathways to destruction
The ubiquitin proteasome system (UPS) plays an essential 
part  both  in  the  normal  turnover  of  proteins  and 
destruction  of  defective  ones,  and  in  the  regulation  of 
cellular  proteins  that  maintain  cell  cycle  progression, 
growth, and survival [2­5]. Proteins destined for degra­
dation  are  tagged  with  ubiquitin  and  delivered  to  the 
proteasome,  a  large  multi­subunit  enzyme  complex 
(Figure  1)  whose  barrel­shaped  catalytic  core  contains 
three  proteolytic  activities  ­  chymotrypsin­like  (CT­L), 
trypsin­like  (T­L)  and  caspase­like  (C­L).  Pharmaco­
logical  inhibition  of  proteasome  function  results  in 
intracellular aggregation of unwanted proteins, and this 
triggers cell death.
Although the proteasome is essential for the regulated 
degradation  of  proteins  whose  cyclic  destruction  is 
required for cell cycle progression, as well as of crucial 
cell  signaling  molecules,  it  is  thought  to  be  the  accu­
mulation of aggregated proteins that is responsible for 
the effectiveness of proteasome inhibition in the treat­
ment of multiple myeloma. Multiple myeloma cells are 
derived from the antibody­producing cells of the immune 
system, and unlike other tumor cells, produce very large 
quantities of protein (the immunoglobulin chains that are 
their specialized product), which makes them unusually 
susceptible to the toxic consequences of inhibiting the 
normal degradative mechanisms. Normal cells can survive 
therapeutic doses of proteasome inhibitors because they 
have a lower rate of proliferation and consequently less 
need for proteasomal regulatory functions [3,4]. More­
over, inhibition of preoteasomal degradation upregulates 
autophagy  [6],  an  alternative  degradative  pathway  that 
delivers long­lived proteins, protein aggregates, and cyto­
plasmic organelles such as mitochondria to lyso  somes for 
destruction [7]. Autophagy, which serves as an emer  gen  cy 
source of energy during metabolic stress or starvation, 
can also contribute to the survival of tumor cells under 
stress [8]. Indeed, inhibition of autophagy enhances the 
induction  of  apoptosis  by  alkylating  agents  and 
irradiation  in  tumor  cells,  and  can  also  synergize  with 
bortezomib [9].
The studies of Zhao and Vuori [10] suggest that Cas 
may  block  this  alternative  pathway  to  survival  in  cells 
treated with proteasome inhibitors.
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Abstract
Current interest in proteasome inhibitors for cancer 
therapy has stimulated considerable research efforts 
to identify the molecular pathway to their cytotoxicity 
with a view to identifying the mechanisms of sensitivity 
and resistance as well as informing the development 
of new drugs. Zhao and Vuori describe this month in 
BMC Biology experiments indicating a novel role of the 
adaptor protein p130Cas in sensitivity to apoptosis 
induced not only by proteasome inhibitors but also by 
the unrelated drug doxorubicin.
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Cas is a docking protein that participates in the trans­
duction  of  integrin­  and/or  cytokine  receptor­induced 
growth and survival signaling [11], and is implicated in 
several pathological conditions, including inflammatory 
disorders,  Alzheimer’s  disease,  Parkinson’s,  develop­
mental  defects,  as  well  as  in  cancer.  Zhao  and  Vuori 
utilized both genetic and biochemical assays to show that 
Cas  is  required  for  proteasome  inhibition­triggered 
apoptosis  (Figure  2).  Specifically,  Cas­deficient  mouse 
embryonic fibroblasts (MEFs) were resistant to MG132­ 
or  bortezomib­induced  cell  death,  while  transfection 
with full length Cas (Cas­FL) restored the sensitivity of 
these  cells  to  proteasome  inhibitors.  These  data  were 
corroborated  with  Cas  small  hairpin  RNA­mediated 
knock  down  experiments  in  other  Cas­expressing  cell 
types  (human  293T  and  HeLa  cells).  This  differential 
biological response in Cas­FL­ and Cas­deficient cells to 
MG132 was not due to disparity in proteasome activity 
inhibition.
Several lines of evidence adduced by Zhao and Vuori 
[10]  indicate  that  the  effect  of  Cas  on  the  apoptotic 
response to proteasome inhibitors involves blockade of 
autophagy.  In  MEFs  lacking  Cas,  bortezomib  triggers 
autophagy instead of apoptosis, but apoptosis is induced 
if autophagy inhibitors are added. Similarly, apoptosis is 
induced by proteasome inhibitors in cells lacking Cas if 
autophagy  is  prevented  by  downregulation  of  Atg5,  a 
protein essential for formation of autophagosomes.
Open questions
The  mechanism  whereby  Cas  mediates  proteasome­
inhibitor­induced  apoptosis  is  not  clear.  One  obvious 
possibility is that the proteasome inhibitors are acting by 
allowing  the  toxic  accumulation  of  protein  aggregates 
which would normally activate the autophagic pathway, 
and by preventing this, Cas is promoting the apoptotic 
response  to  the  resulting  stress.  However,  Zhao  and 
Vuori  found  similar  effects  of  Cas  in  response  to  the 
DNA  damaging  agent  doxorubicin,  suggesting  that  the 
role  of  Cas  in  response  to  apoptotic  stimuli  extends 
beyond that induced by proteasome inhibitors.
Earlier studies have shown that proteasome inhibition 
promotes  Abl­mediated  phosphorylation  of  Crk,  dis­
assembly of Cas­Crk complexes (cell migration/survival 
pathway), and cell death [12]. A role for c­Abl has also 
been reported in response to DNA­damaging agents such 
as ionizing radiation (IR) and alkylating agents such as 
cisplatin. Whether proteasome inhibition or doxorubicin 
affects c­Abl and Cas­Crk assembly resulting in cell death 
requires  further  examination.  Similarly,  the  effect  of 
proteasome  inhibition  on  the  role  of  Cas­associated 
proteins that are regulated by the ubiquitin ligase c­Cbl 
remains  to  be  evaluated.  The  data  showing  that  doxo­
rubicin has the same effect as proteasome inhibitors in 
Cas­FL and Cas­deficient MEFs suggests that Cas can be 
regulated by mechanism(s) independent of proteasome 
inhibition as well. Nonetheless, the findings of Zhao and 
Vuori provide compelling evidence of a direct link between 
Cas and proteasome inhibition­triggered cytotoxicity.
Zhao and Vuori have been able to rule out one possible 
contribution  of  Cas  to  the  apoptotic  response  to 
proteasome inhibition and doxorubicin. Cas has a known 
proapoptotic  activity  that  has  been  attributed  to  its 
cleaved form (Cas­CT), and MG132 indeed induces Cas­
CT. In contrast to earlier reports, however, this is not 
required  for  the  induction  of  apoptosis  since  the 
overexpression of cleavage­resistant Cas mutants in Cas­
deficient MEFs increases sensitivity to MG132.
The mechanism of the effects of Cas on the apoptotic 
response and on autophagy thus remains unclear, and the 
answer may require an understanding of the role of Cas 
Figure 1. Schematic representation of protein degradation by 
the proteasome. Proteins are tagged for degradation by regulated 
ubiquitylation, which directs them to binding sites on the 19S 
regulatory subunits where they are unfolded for degradation in the 
barrel-shaped 20S catalytic core.
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Page 2 of 4in normal cells in vivo. Cas is an integral molecule linking 
integrin  or  extracellular  matrix­mediated  growth  and 
survival  signaling,  and  disruption  of  this  adhesion­
regulated pathway, or lack of Cas, may cause detachment­
induced  cell  death  (anoikis)  and/or  autophagy.  Other 
focal  adhesion  proteins,  such  as  paxillin,  have  been 
implicated  in  autophagosome  formation;  and  Cas 
interacts with paxillin. This interplay between Cas and 
paxillin  or  other  focal  adhesion  kinases  (FAKs)  may 
provide an additional link to autophagy.
In any case, it is clear that the specific conditions and 
cellular context will be important in the influence of Cas 
on tumor cell survival and drug sensitivity. A number of 
previous studies, as Zhao and Vuori acknowledge, have 
shown an association of aberrant expression of Cas with 
tumor cell survival and drug resistance. For example, the 
overexpression  of  Cas  activates  growth  and  survival 
signaling  pathways  via  phosphoinositide  3­kinase/Akt, 
ERK1/2, epidermal growth factor receptor, Rac, or Src, 
conferring  doxorubicin  or  tamoxifen  resistance  [11]; 
activation and aberrant expression of Cas correlates with 
tumor progression and metastasis; and overexpression is 
associated with poor prognosis and resistance to primary 
chemotherapeutic treatment in breast, lung, and prostate 
cancer,  as  well  as  glioblastoma  and  melanoma.  This 
apparent conflict with the pro­apoptotic influence of Cas 
in the experiments reported by Zhao and Vuori may reflect 
aberrant  effects  of  overexpression,  or  cell­type­specific 
effects, or both. Moreover, the observations of Zhao and 
Vuori are so far confined to mouse embryo fibroblasts, 
and  will  require  further  validation  using  primary  cells 
from patients, as well as in vivo animal models, in order 
to  assess  clinical  relevance.  Quantitative  assessment  of 
Cas  protein  levels  in  patient  tumor  cells  and  their 
correlation with sensitivity to proteasome inhibitors may 
then  provide  further  insight  into  selecting  patient 
populations likely to respond. It is also worth pointing 
out that autophagy can help kill cells as well as rescue 
them [8].
Future studies in various cancer cell types examining 
Cas  expression  and  associated  responsiveness  to 
proteasome  inhibitors  (and  other  drugs)  may  help  to 
inform clinical trials of autophagy inducers or inhibitors 
in combination therapies.
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Figure 2. Effects of bortezomib, MG132 or doxorubicin on mouse embryonic fibroblasts overexpressing Cas (Cas+/+) and Cas-deficient 
mouse embryonic fibroblasts (Cas-/-). shRNA, short hairpin RNA.
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